Rx Product News

Published Online: Wednesday, October 9, 2013
Follow Pharmacy_Times:



Fetzima

Marketed by: Forest Laboratories, Inc.
Indication: The FDA has approved Fetzima (levomilnacipran), a serotonin and norepinephrine reuptake inhibitor for the treatment of major depressive disorder. Fetzima is not approved for the management of fibromyalgia. The recommended dose is 40 to 120 mg once daily with or without food. Dosing should be initiated by taking 20 mg once daily for 2 days. Capsules should be swallowed whole.
Dosage Form: Extended-release capsules: 20, 40, 80, and 120 mg
For More Information: https://fetzima.com







Epaned
Marketed by: Silvergate Pharmaceuticals, Inc
Indication: The FDA has approved Epaned (enalapril), an angiotensin-converting enzyme inhibitor for the treatment of hypertension in adults and children older than 1 month. The recommended initial dose in adults is 5 mg once daily, with a maximum dose of 40 mg/day. In children, the recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily.
Dosage Form: Powder for oral solution: 150 mg of enalapril maleate in a 150 mL bottle; reconstitution with 150 mL of ORA-SWEET SF results in a 1 mg/mL oral solution
For More Information: www.SilvergatePharma.com




Oseni
Marketed by: Takeda Pharmaceuticals America, Inc
Indication: The FDA has approved Oseni—a dipeptidyl peptidase-4 inhibitor and thiazolidinedione combination product—as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Oseni is not indicated for treating type 1 diabetes mellitus or diabetic ketoacidosis. The starting dose should be individualized to the patient, but a daily dose of alogliptin 25 mg and pioglitazone 45 mg should not be exceeded.
Dosage Form: Tablets (mg alogliptin/mg pioglitazone): 25/15, 25/30, 25/45, 12.5/15, 12.5/30, 12.5/45
For More Information: www.takeda.us/products/default.aspx




FluLaval Quadrivalent

Marketed by: GlaxoSmithKline
Indication: The FDA has approved FluLaval Quadrivalent, a vaccine indicated for active immunization to prevent disease caused by influenza A subtype viruses and type B viruses in persons 3 years and older. The recommended dose in children 3 through 8 years of age who have not been vaccinated against influenza is 2 doses (0.5 mL each) at least 4 weeks apart. For more details, see the manufacturer’s prescribing information.
Dosage Form: Suspension for injection in 5-mL multidose vials containing ten 0.5-mL doses
For More Information: http://us.gsk.com/html/medicines/index.html#vaccineshttp://us.gsk.com/products/assets/us_flulaval_ quadrivalent.pdf

Related Articles
Mylan has announced the US launch of its lamivudine tablets, the generic version of GlaxoSmithKline's hepatitis B virus (HBV) treatment, Epivir-HBV.
Evidence released by the manufacturers of Tamiflu and Relenza has raised questions concerning the drugs' efficacy and safety.
GSK has announced the winners of its second Discovery Fast Track Challenge - a program designed to combine the expertise of academic researchers with that of drug discovery scientists at GSK, to accelerate the search for new medicines.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$